NFKB1 and type 1 diabetes mellitus: IMD treatment reversed advanced glycation end products-mediated M1 macrophage polarization and impaired bone regeneration in type 1 diabetes mellitus (T1DM), which was partially achieved by the peroxisome proliferator-activated receptor γ (PPARγ)-mediated inhibition of NF-κB signaling (Wang et al., 2021).